Back to the news

OncoDNA has inked a distribution agreement with GENEXT LLC (Russia)

January 29th, 2019

GENEXT will market and distribute OncoDNA’s solutions to oncologists and their patients in Russian Federation

OncoDNA, the Cancer Theranostic Company, said today that it has inked a distribution agreement with GENEXT LLC (Russia), a company offering a wide range of high-quality clinical, molecular testing services to meet diagnostic and treatment planning requirements. GENEXT LLC will market and distribute OncoDNA’s solutions to oncologists and their patients in Russian Federation.
Russian oncologists will have access to the state-of-the-art molecular profiling program that combines analysis of liquid and solid biopsies in order to improve the lives of patients with metastatic cancer. Patients will benefit from the personalized medicine approach based on the most comprehensive tumour profiling solution.

“We are continuing the expansion of our distributor network, with strong background in oncology. GENEXT is the right partner for us to promote our solutions in Russia. Local clinicians can rely on the combined expertise of GENEXT and OncoDNA to help them provide their patients with the most efficient care, extending and improving their quality of life”, says Fiona Demol, International Business Development Manager at OncoDNA.
“This agreement enables us to expand our product offering to oncologists and patients with an extensive range of high-quality, proven molecular diagnostic solutions. We are pleased to work with OncoDNA to offer their cutting edge advanced solutions to Russian patients.” Says Vitali Proutski, CEO at GENEXT LLC.

If you are a medical doctor from the region (Russia and CIS) and you would like to discuss potential collaboration, please contact GENEXT LLC (OncoDNA’s distributer in Russia): + 7 (965) 080 72 77, or

GENEXT LLC is a young and innovative service company created in 2015 and specializing in high-value molecular diagnostics. It offers to its customers comprehensive access to a range of validated tests with proven clinical utility and originating from the best providers of molecular diagnostics in the field of oncology and non-invasive prenatal testing (NIPT). These tests allow physicians and their patients to evaluate the risk of disease onset, assess its prognosis and chose the optimal treatment strategy based on the genetic characteristics of patients and using cutting-edge molecular profiling technologies.

More information at